PATENT CLAIM ANALYSIS

Application Number: 15875362
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["506", "009000"]

Abstract:
A method of diagnosing cancer in a mammal is provided. The method includes the steps of determining in a nucleic acid-containing sample from the mammal the degree of DNA methylation of a target region within the hTERT promoter from the nucleotide at about position −157 to the nucleotide at about position −580, or a corresponding target region in a TERT promoter in a mammal other than a human, to yield a sample methylation signature, determining the baseline degree of DNA methylation of the target region in a control sample to yield a control methylation signature, comparing the sample methylation signature to the control methylation signature and rendering a diagnosis of cancer when there is at least 1.5 times more methylation in the sample methylation signature as compared to the control methylation signature. Methods of determining tumour grade and progression, predicting survival and determining whether or not a mammal is a candidate for telomerase-targeted or demethylation therapy are also provided.

Claim (Index 1):
A method of diagnosing cancer, predicting tumour progression from benign to malignant, predicting the grade of a tumour, or predicting survival in a human, said method comprising the steps of:\n i) determining in a nucleic acid sample from the human the degree of DNA methylation of CG sites within the TERT promoter to yield a sample methylation signature, wherein the sample is optionally amplified and the degree of methylation is determined by sequencing using PCR and/or sequencing primers comprising at least 15 nucleotides which target a nucleotide region of the TERT promoter that is free of CG sites selected from the nucleotide regions: \u2212142 to \u2212156, \u2212231 to \u2212262, \u2212292 to \u2212314, \u2212345 to \u2212404 or \u2212592 to \u2212615 of the TERT promoter; ii) determining the baseline degree of DNA methylation of the TERT promoter in a control sample to yield a control methylation signature; and iii) comparing the sample methylation signature to the control methylation signature and diagnosing cancer, identifying a tumour to be a malignant tumour, or predicting a 5-10 year overall survival or progression-free survival of less than 50% when there is at least 1.5 times more methylation in the sample methylation signature in a region of the hTERT promoter consisting of from the nucleotide at about position \u2212157 to the nucleotide at about position \u2212580 as compared to the control methylation signature.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 86.0
- Lexical Diversity: 2.28767
- Patent Class: 506.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14403802', '13796864', '14180239', '14407541', '11667628']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5442713768559445
- 35 USC 102 Novelty (BERT): 0.6317231875881956
- Combined Prediction Score: 0.5530165579291696
- Mean Citation Score: 338.411278
- Max Citation Score: 609.5144
- Similarity Product: 523.7135918276787

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test